22 May 2013
Keywords: Eli Lilly, Pomaglumetad methionil, Schizophrenia, R&D charge
Article | 30 August 2012
US drug major Eli Lilly (NYSE: LLY) saw its shares dip less than 1% to $44.51 in morning trading yesterday, as the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
30 August 2012
21 May 2013
© 2013 thepharmaletter.com